# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Mumtaz Mahal (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-RE006-SYN-TD
- Date: 1631-06-02
- Fictional facility: St. Posthumous Health Center
- Fictional author: Farzana Qureshi-Lindholm, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Prenatal visit at 34 weeks after six weeks of travel; growth scan and birth planning. **S**

## History of present illness

Mumtaz Mahal returns at 34 weeks 2 days, three days after coming back from six weeks of travel with her family. The visits planned at 30 and 32 weeks did not take place: the family moved several times and no clinic was arranged, and no blood pressure was checked while she was away. She has felt well. She has had no headache, visual change, upper abdominal pain, swelling of the face or hands, breathlessness, bleeding, leaking fluid, or regular contractions; she has occasional painless tightenings, and the baby moves often. She took aspirin and folic acid throughout. The test-of-cure urine culture sent before she left grew nothing. She is staying in the city until the birth. She had the growth scan this morning. She has thought about the future and says she wants her body to rest after this baby. **S**

| Element | Detail |
|---|---|
| Travel | Six weeks away; the 30- and 32-week visits were missed |
| Symptoms | None of preeclampsia; occasional painless tightenings |
| Fetal movement | Frequent |
| Urine | Test-of-cure culture: no growth |
| Plans | Staying near the hospital until the birth |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Well; no fever |
| Cardiovascular | Negative | No breathlessness or palpitations |
| Neurological | Negative | No headache or visual change |
| Gastrointestinal | Negative | No upper abdominal pain or vomiting |
| Genitourinary | Negative | No bleeding, leaking fluid, or urinary symptoms |
| Psychiatric | Negative | Calm and hopeful; EPDS 5 |

6 systems reviewed. **S**

## Current medications

- Folic acid 0.4 mg oral tablet, one tablet by mouth daily **S**
- Aspirin 81 mg delayed-release tablet, one tablet by mouth at bedtime **S**

## Allergies

- No known allergy **S**

## Objective

BP 112/70 mmHg; pulse 88 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 99% on room air; weight 68 kg; BMI 27.6 kg/m². All vital signs are synthetic.

Hemoglobin: 11.8 g/dL; Platelets: 228 10*3/uL; EPDS: 5; Estimated fetal weight: 2380 g. All results are synthetic.

## Change since baseline

- Hemoglobin: 10.1 g/dL (low) at baseline, 11.8 g/dL at this visit **S**
- Platelets: 245 10*3/uL at baseline, 228 10*3/uL at this visit **S**
- EPDS: 8 at baseline, 5 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well |
| Abdomen | Fundal height 34 cm; cephalic by palpation; non-tender |
| Fetal | Scan: cephalic, estimated weight 2380 g (about the 45th centile), normal amniotic fluid; fetal heart 140 per minute |
| Extremities | Trace ankle edema; no calf tenderness |
| Urine dipstick | Protein negative |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Fourteenth pregnancy at 37** (O09.529). Blood pressure 112/70 mmHg, urine protein negative, and no symptoms of preeclampsia after the missed visits. Normal growth on the 45th centile, cephalic, normal fluid. Hemoglobin 11.8 g/dL and platelets 228. EPDS 5 with item 10 scored 0. **S**
   - Weekly visits from now until the birth, with blood pressure and urine protein each time.
   - Group B streptococcus swab at 36 to 37 weeks.
   - Weekly fetal heart rate monitoring from 36 weeks, which can be offered at her age.
   - Induction of labor at 39 weeks at the hospital, which she chose after discussing the options; continue aspirin until delivery.
2. **Grand multiparity: postpartum hemorrhage risk** (O09.40). Postpartum hemorrhage risk assessment: thirteen previous vaginal births (a major risk factor for uterine atony); anemia now corrected; no previa, accreta, multiple pregnancy, or large baby; no bleeding disorder; no previous hemorrhage that she knows of. Medium risk. **S**
   - Birth at the hospital, which has a blood bank, 24-hour anesthesia, and an operating theatre; she will not travel again before the birth.
   - On admission: blood count, type and screen, and two large-bore intravenous lines.
   - Labor: timely assessment of progress so that labor is not prolonged; her past labors were short, so she should come in at the first regular contractions.
   - Third stage: oxytocin 10 units intramuscularly or intravenously as the baby is born, controlled cord traction, uterine tone checks, and quantitative measurement of blood loss.
   - If hemorrhage is diagnosed (blood loss of 1000 mL or more, or any loss with signs of shock): tranexamic acid 1 g intravenously over 10 minutes within 3 hours of birth, a second 1 g dose if bleeding continues after 30 minutes or restarts within 24 hours, uterine massage, second-line uterotonics, and escalation through the hemorrhage protocol.
   - Anesthesia consultation at 36 weeks.
3. **Short interpregnancy interval** (O09.899). She wants her body to rest and does not want another pregnancy for at least two years; she has not decided whether she wants more children. She asked which methods are acceptable within her faith; we discussed that many Muslim scholars permit reversible contraception, and she can speak with a religious adviser of her choosing. **S**
   - Options reviewed: implant, hormonal or copper IUD, progestin-only pill, injection, lactational amenorrhea, and permanent methods.
   - She chose an etonogestrel implant placed before she leaves hospital after the birth; it is safe with breastfeeding.
   - Advised waiting at least 18 months, and preferably 24 months, after this birth before any future pregnancy.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure and urine protein | Every prenatal visit | Completed today | 112/70 mmHg; urine protein negative |
| Examination | Blood pressure and fetal checks at 30 and 32 weeks | Every two weeks from 28 to 36 weeks | Deferred | Missed: the 30- and 32-week visits did not take place during six weeks of family travel, and no blood pressure was recorded. No harm found today: blood pressure 112/70 mmHg, no proteinuria, no symptoms, and normal growth on the scan. Corrective action: weekly visits until the birth, a home blood pressure cuff with readings to call in, and she will stay near the hospital |
| Examination | Fetal heart and fundal height | Every prenatal visit | Completed today | Fetal heart 140 per minute; fundal height 34 cm; cephalic |
| Examination | Weight gain | Every prenatal visit | Completed today | 68.0 kg, up 9.4 kg since intake |
| Laboratory | Hemoglobin and ferritin | At intake, four weeks after starting treatment, at 24 to 28 weeks, and before delivery | Completed today | Hemoglobin 11.8 g/dL: anemia corrected before delivery; platelets 228 |
| Imaging | Third-trimester growth scan | At about 32 to 34 weeks | Completed today | Estimated weight 2380 g, about the 45th centile; cephalic; normal fluid |
| Laboratory | Urine culture test of cure | One to two weeks after treatment | Completed today | No growth (sent at the 27-week visit) |
| Laboratory | Group B streptococcus culture | At 36 0/7 to 37 6/7 weeks | Due | At the 36-week visit |
| Survey | Perinatal mood screen (EPDS) | Each trimester | Completed today | 5; item 10 scored 0 |
| Medication safety | Low-dose aspirin | Daily from 12 to 16 weeks until delivery; review at every visit | Completed today | Taken nightly; continue until delivery |
| Self-management | Postpartum hemorrhage risk assessment and birth plan | At intake, in the third trimester, and on admission for birth | Completed today | Medium risk from grand multiparity; written plan agreed: hospital birth, oxytocin, quantitative blood loss, tranexamic acid within 3 hours if hemorrhage occurs |
| Referral | Anesthesia consultation | In the third trimester for a patient at increased risk of hemorrhage | Due | Booked for 36 weeks |
| Self-management | Postpartum contraception and interpregnancy interval | Before delivery | Completed today | Etonogestrel implant before discharge; at least 18 to 24 months before any future pregnancy |

## Goal progress

- Hemoglobin at least 11 g/dL with replete iron stores before delivery. Outcome by 1631-06-02: Hemoglobin 11.8 g/dL and ferritin 110 ng/mL after two doses of intravenous iron. **S**
- An informed choice about aneuploidy screening by 14 weeks. Outcome by 1631-02-03: Chose cell-free DNA (low risk) with the nuchal translucency scan (1.7 mm); declined diagnostic testing. **S**
- Blood pressure below 140/90 mmHg with aspirin taken nightly from 13 weeks. In progress; target 1631-07-12. **S**
- A written delivery and postpartum hemorrhage plan agreed by 36 weeks, with birth planned in a hospital with a blood bank and operating theatre. Outcome by 1631-06-02: Plan agreed at 34 weeks: induction at 39 weeks at the hospital, oxytocin after birth, quantitative blood loss, and tranexamic acid ready. **S**
- A postpartum contraception choice and a plan for the interval before any future pregnancy, made on her own terms before delivery. Outcome by 1631-06-02: Chose an etonogestrel implant before discharge after the birth; plans at least 18 to 24 months before any future pregnancy. **S**

## Guideline basis

- Pregnancy at Age 35 Years or Older: ACOG Obstetric Care Consensus No. 11 (2022), American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine (Obstetrics & Gynecology)
- Practice Bulletin No. 183: Postpartum Hemorrhage (2017), American College of Obstetricians and Gynecologists (Obstetrics & Gynecology)
- WHO recommendations for the prevention and treatment of postpartum haemorrhage (2012), World Health Organization
- WHO recommendation on tranexamic acid for the treatment of postpartum haemorrhage (2017), World Health Organization
- Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial (2017), WOMAN Trial Collaborators (The Lancet)
- Obstetric Care Consensus No. 8: Interpregnancy Care (2019), American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine (Obstetrics & Gynecology)
- U.S. Medical Eligibility Criteria for Contraceptive Use, 2024 (2024), Centers for Disease Control and Prevention

## Follow-up

- Weekly prenatal visits from next week until the birth; induction at 39 weeks at the hospital. **S**

